For Patients
Biodexa Pharmaceuticals focuses on treatments for familial adenomatous polyposis (FAP), type 1 diabetes, and brain cancers.
biodexapharma.comCrawled Nov 22, 2026
Biodexa Pharmaceuticals focuses on treatments for familial adenomatous polyposis (FAP), type 1 diabetes, and brain cancers.
Thankfully, numerous brain cancer support groups exist providing a network of understanding, guidance, and comfort.
The page provides information on Biodexa Pharmaceuticals’ current clinical trials.
Biodexa Pharmaceuticals offers a Named Patient Programme for eRapa (encapsulated rapamycin).
The company’s lead development programme, eRapa, is being readied for a phase 3 registration study in familial adenomatous polyposis (FAP).
Familial adenomatous polyposis (FAP) is an inherited condition increasing colorectal cancer risk through colon and rectal polyps.
The page discusses challenges in clinical trial recruitment and strategies to address them.
Ethical considerations or ethics are paramount in ensuring the well-being and rights of participants in clinical trials.
Glioblastoma (or Glioblastoma multiforme), often abbreviated as GBM, stands as one of the most aggressive and challenging brain tumors.
In the vast landscape of healthcare, rare and orphan diseases often remain unseen and overlooked. Yet, they affect millions of people.
The page describes how clinical trials advance medical research and discover treatments for health conditions.
An Update to MTX110 Study in Pediatric Patients with DIPG . Biodexa Pharmaceuticals .
Biodexa Pharmaceuticals PLC Announces Closing of $3.32 Million Registered Direct Offering . Biodexa Pharmaceuticals .
First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma . Biodexa Pharmaceuticals .
IND Application for MTX110 Study in GBM Effective . Biodexa Pharmaceuticals .
Midatech Pharma welcomes Dr Dmitry Zamoryakhin as Chief Scientific Officer . Biodexa Pharmaceuticals .
MTX110 Update & Headline Results for 2020 . Biodexa Pharmaceuticals .
Biodexa Pharmaceuticals lists current job openings on its website.
Biodexa Pharmaceuticals highlights its experienced team, featuring Simon Turton.
Biodexa Pharmaceuticals highlights its experienced team, featuring Ann Merchant.
Biodexa Pharmaceuticals highlights its experienced team, featuring Fiona Sharp.
Biodexa Pharmaceuticals highlights its experienced team, featuring Gary Shangold.
Biodexa Pharmaceuticals highlights its experienced team, featuring Stephen Stamp.
Biodexa Pharmaceuticals highlights its experienced team, featuring Steve Ellul.
Biodexa Pharmaceuticals aims to develop medicines for patients with serious, unmet medical needs.
Registered Office and Trading Address: Biodexa Pharmaceuticals PLC, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Biodexa Pharmaceuticals is a clinical stage biopharma company developing a pipeline of treatments for diseases with high unmet clinical need.
Biodexa Pharmaceuticals outlines its privacy policy on its website.
Biodexa Pharmaceuticals develops treatments for Familial Adenomatous Polyposis (FAP) and malignant gliomas.